BridgeBio launches CoA Therapeutics to treat a rare neurodegenerative disease
Thursday, July 5, 2018 - 18:16
in Health & Medicine
The startup is developing allosteric activators to increase levels of the vital metabolic molecule coenzyme A in pantothenate kinase-associated neurodegeneration